EMA Recommends Extension of Indications for Serplulimab By Ogkologos - April 22, 2026 52 0 Facebook Twitter Google+ Pinterest WhatsApp New indications concern the treatment of patients with oesophageal squamous cell carcinoma and non-small cell lung cancer Source RELATED ARTICLESMORE FROM AUTHOR ESMO Advocates for Equal Access to Optimal Cancer Care for all Patients with Cancer at the 79th World Health Assembly Daraxonrasib Shows Antitumour Activity Among Patients with Previously Treated RAS-mutated Pancreatic Ductal Adenocarcinoma FDA Approves Vepdegestrant for ER-positive, HER2-negative, ESR1-mutated Advanced or Metastatic Breast Cancer MOST POPULAR Mother Spent 14 Weeks Battling Breast Cancer Alone During COVID-19 Lockdown October 20, 2020 Five Questions With…Sharon. May 12, 2022 Cómo pueden sobrellevar la ansiedad provocada por una exploración las personas... August 4, 2022 Dabrafenib–Trametinib Combination Approved for Melanoma, Anaplastic Thyroid Cancer May 25, 2018 Load more HOT NEWS FDA Approves Mitomycin Intravesical Solution for Recurrent Low Grade Intermediate Risk... Using Immunotherapy to Treat Advanced Melanoma and Advanced Non-Small Cell Lung... For Children with Neuroblastoma, Trial Results Highlight Continued Evolution of Treatment The Right to be Forgotten: ESMO Calls on EU Countries to...
